[{"abstract": "The company has been growing steadily, but investors are certain to start agitating again to complete a bold move in order to push growth higher.", "web_url": "https://www.nytimes.com/2016/04/07/business/dealbook/pfizer-allergan-merger.html", "snippet": "The company has been growing steadily, but investors are certain to start agitating again to complete a bold move in order to push growth higher.", "lead_paragraph": "Pfizer needs a Plan C.", "print_section": "B", "print_page": "1", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2016/04/07/business/db-pfizer2/db-pfizer2-articleLarge.jpg", "height": 407, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2016/04/07/business/db-pfizer2/db-pfizer2-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 407}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2016/04/07/business/db-pfizer2/db-pfizer2-jumbo.jpg", "height": 695, "width": 1024, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2016/04/07/business/db-pfizer2/db-pfizer2-superJumbo.jpg", "height": 1254, "width": 1848, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2016/04/07/business/db-pfizer2/db-pfizer2-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2016/04/07/business/db-pfizer2/db-pfizer2-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2016/04/07/business/db-pfizer2/db-pfizer2-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "Pfizer Faces Limited Options After Its Dead Deal With Allergan", "kicker": null, "content_kicker": null, "print_headline": "Pfizer Weighs Split as Allergan Deal Collapses", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "organizations", "value": "Pfizer Inc", "rank": 1, "major": "N"}, {"name": "persons", "value": "Bray, Chad", "rank": 2, "major": "N"}, {"name": "organizations", "value": "Allergan Inc (ALL CAPS)", "rank": 3, "major": "N"}, {"name": "persons", "value": "Thomas, Katie", "rank": 4, "major": "N"}, {"name": "organizations", "value": "ALLERGAN INC", "rank": 5, "major": "N"}, {"name": "subject", "value": "Corporate Taxes", "rank": 6, "major": "N"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 7, "major": "N"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 8, "major": "N"}, {"name": "organizations", "value": "ALLERGAN INC", "rank": 9, "major": "N"}], "pub_date": "2016-04-06T11:21:45+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "subsection_name": "DealBook", "byline": {"original": "By Katie Thomas and Chad Bray", "person": [{"firstname": "Katie", "middlename": null, "lastname": "Thomas", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}, {"firstname": "Chad", "middlename": null, "lastname": "Bray", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 2}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/b82fed4d-90ed-5116-af2e-b52ed86af37b", "word_count": 929, "uri": "nyt://article/b82fed4d-90ed-5116-af2e-b52ed86af37b"}, {"abstract": "Now that the merger between the pharmaceutical giants is dead, their bankers will receive about 10 percent of their fees, according to estimates.", "web_url": "https://www.nytimes.com/2016/04/07/business/dealbook/pfizer-and-allergan-advisers-lose-out-on-200-million-in-fees.html", "snippet": "Now that the merger between the pharmaceutical giants is dead, their bankers will receive about 10 percent of their fees, according to estimates.", "lead_paragraph": "A collective sigh \u2014 and most likely some profanity \u2014 echoed across Wall Street on Wednesday after Pfizer and Allergan terminated the biggest deal in 15 years and federal regulators sought to break up another large deal on antitrust grounds.", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2016/04/07/business/07db-fees/07db-fees-articleLarge.jpg", "height": 401, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2016/04/07/business/07db-fees/07db-fees-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 401}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2016/04/07/business/07db-fees/07db-fees-jumbo.jpg", "height": 684, "width": 1024, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2016/04/07/business/07db-fees/07db-fees-superJumbo.jpg", "height": 1368, "width": 2048, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2016/04/07/business/07db-fees/07db-fees-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2016/04/07/business/07db-fees/07db-fees-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2016/04/07/business/07db-fees/07db-fees-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "Pfizer and Allergan Advisers Lose Out on $200 Million in Fees", "kicker": null, "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Banking and Financial Institutions", "rank": 1, "major": "N"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 2, "major": "N"}, {"name": "subject", "value": "Antitrust Laws and Competition Issues", "rank": 3, "major": "N"}, {"name": "subject", "value": "Regulation and Deregulation of Industry", "rank": 4, "major": "N"}, {"name": "organizations", "value": "ALLERGAN INC", "rank": 5, "major": "N"}, {"name": "organizations", "value": "Pfizer Inc", "rank": 6, "major": "N"}, {"name": "organizations", "value": "Halliburton Company", "rank": 7, "major": "N"}, {"name": "organizations", "value": "Baker Hughes Inc", "rank": 8, "major": "N"}], "pub_date": "2016-04-06T18:36:39+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "subsection_name": "DealBook", "byline": {"original": "By Leslie Picker", "person": [{"firstname": "Leslie", "middlename": null, "lastname": "Picker", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/2ced1210-ae8a-5b58-954c-8a05285c2f53", "word_count": 468, "uri": "nyt://article/2ced1210-ae8a-5b58-954c-8a05285c2f53"}, {"abstract": "In the abandoned merger with Allergan, lawmakers, the Treasury Department and Pfizer itself bear some responsibility.", "web_url": "https://www.nytimes.com/2016/04/07/business/dealbook/finger-pointing-abounds-in-failed-pfizer-deal.html", "snippet": "In the abandoned merger with Allergan, lawmakers, the Treasury Department and Pfizer itself bear some responsibility.", "lead_paragraph": "Pfizer\u2019s abandoned deal leaves all sides tainted.", "source": "The New York Times", "multimedia": [], "headline": {"main": "Finger-Pointing Abounds in Failed Pfizer Deal", "kicker": "Breakingviews", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "organizations", "value": "Pfizer Inc", "rank": 1, "major": "N"}, {"name": "organizations", "value": "ALLERGAN INC", "rank": 2, "major": "N"}, {"name": "organizations", "value": "Treasury Department", "rank": 3, "major": "N"}, {"name": "persons", "value": "Read, Ian C", "rank": 4, "major": "N"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 5, "major": "N"}, {"name": "subject", "value": "Taxation", "rank": 6, "major": "N"}], "pub_date": "2016-04-06T19:19:15+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "subsection_name": "DealBook", "byline": {"original": "By Robert Cyran", "person": [{"firstname": "Robert", "middlename": null, "lastname": "Cyran", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/db227162-6882-5514-8d8d-3286bb786631", "word_count": 366, "uri": "nyt://article/db227162-6882-5514-8d8d-3286bb786631"}]